BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Nov. 8, 2005--Akorn, Inc. (AMEX:AKN) today announced that it has signed a Letter of Intent with Cipla, Ltd., a leading Indian pharmaceutical company located in Mumbai, India, to develop and supply an oral anti-infective ANDA drug product. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Cipla.
